Context Therapeutics Inc.
HealthcareNASDAQ:CNTX · NASDAQ Capital Market
-$0.03 today
Vol 0.50M · Avg 0.80M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-59.7%
avg -52.4%
ROIC
-65.5%
avg -3.4%
ROA
-52.7%
avg -171.5%
Analysis
ROA is currently the strongest return metric at -52.7% versus its period average of -171.5%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Martin A. Lehr | Co-Founder, President, Chief Executive Officer & Director | $914,015.00 | — | 42 | $815,000.00 | 0.89% |
Jennifer Minai-Azary | Chief Financial Officer & Treasurer | $610,731.00 | — | 48 | $275,000.00 | 0.30% |
Alex C. Levit | Chief Legal Officer & Corporate Secretary | $576,307.00 | — | 47 | $270,000.00 | 0.29% |
Karen Chagin | Chief Medical Officer | $26,610.00 | — | 49 | $290,000.00 | 0.32% |
Christopher Beck | Senior Vice President of Operations | — | — | — | — | — |
Jeffrey Liebman | Associate Director of Accounting | — | — | — | — | — |
Jennifer Dashnau | Senior Vice President of Technical Operations | — | — | — | $275,000.00 | 0.30% |
Insider Trading
SEC Form 4 transactions — last 12 months
No insider transactions in the last 12 months.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A5 analysts |
| Revenue | N/A | N/A | N/A | N/A6 analysts |
| Net Income | N/A | N/A | N/A | N/A6 analysts |
| EBIT | N/A | N/A | N/A | N/A6 analysts |
Analysis
Analysis will appear once historical growth or forward estimates are available for this company.
Competitors
Peer companies in the same sector
Ovid Therapeutics Inc.
NASDAQ:OVID
$303.33M
MacroGenics, Inc.
NASDAQ:MGNX
$251.71M
Shattuck Labs, Inc.
NASDAQ:STTK
$236.64M
Whitehawk Therapeutics Inc
NASDAQ:WHWK
$205.72M
Oramed Pharmaceuticals Inc.
NASDAQ:ORMP
$158.38M
Connect Biopharma Holdings Limited
NASDAQ:CNTB
$133.48M
InflaRx N.V.
NASDAQ:IFRX
$115.57M
Kalaris Therapeutics Inc
NASDAQ:KLRS
$80.98M
ImageneBio Inc
NASDAQ:IMA
$63.39M
Clene Inc.
NASDAQ:CLNN
$60.20M
Who manages CNTX?
Context Therapeutics Inc. (CNTX) lists 7 active executives. The top listed executive is Alex C. Levit, Chief Legal Officer & Corporate Secretary.
Are CNTX insiders buying or selling?
Recent insider activity shows net buying of $8.59M.
Explore More
Continue the stock analysis
Jump to another research area for this company.